The Pentagon is mandating hormone injections for hundreds of thousands of soldiers, and the medical evidence against it keeps piling up.

"It's about restoring and optimizing your natural capability."

— Pete Hegseth, Secretary of War, introducing mandatory testosterone screening for all troops age 30 and older

On July 18, 2026, Defense Secretary Pete Hegseth announced that every service member age 30 and older would receive mandatory annual testosterone screening, with hormone replacement therapy available for anyone who tests low. Troops under 30 may volunteer for screening. The initiative was branded "The High-T Department of War," delivered via a promotional video in which Hegseth insisted the policy would ensure soldiers have "the biological foundation required to sustain the fight."

The Pentagon provided no peer-reviewed evidence that routine testosterone supplementation improves combat readiness. It did not assess the fertility consequences that can follow treatment. It did not address what happens when service members leave the military and require continued hormone therapy. It did not account for women, who also produce testosterone and fall under the screening mandate.

The medical establishment, by contrast, has been unanimous: universal testosterone screening for asymptomatic adults is not recommended, and the VA had already been flagged for mismanaging the very same treatment.

Less than 6 percent of men between 30 and 79 actually have a clinically significant testosterone deficiency. The Endocrine Society explicitly opposes starting testosterone therapy in men planning to father children, because the treatment suppresses sperm production. Yet the Pentagon is preparing to screen a population that is overwhelmingly young, predominantly male, and largely in the prime of their reproductive years.

Translation: Hegseth is offering a treatment that can cause infertility to the same demographic he claims is too soft to fight, without showing any evidence it helps them fight.

Dr. Adrian Dobs, a professor of medicine and oncology at Johns Hopkins University School of Medicine, told The Intercept that testosterone therapy creates a medical dependency. Once a person starts exogenous testosterone, the body reduces its natural production. Stopping the treatment abruptly is not an option. "We're sort of creating a dependency on testosterone," Dobs said.

Dr. Alvin Matsumoto, a professor emeritus at the University of Washington and former attending physician at the VA Puget Sound Health Care System, helped develop the Endocrine Society's clinical guidelines for testosterone treatment. He said one of the central problems with the Pentagon's approach is that testosterone levels fluctuate dramatically depending on when a person is tested, whether they have recently eaten or exercised, or if they are sick. In approximately one-third of men whose initial test comes back low, a second test produces a normal result.

"Initiating testosterone therapy in men who have a single low testosterone test but no clinical manifestations of testosterone deficiency will likely result in treatment of some men who do not have hypogonadism," Matsumoto said.

The Endocrine Society's guidance is clear: doctors should establish symptoms and repeatedly low levels before beginning treatment. Hegseth's mandate replaces clinical judgment with a blood draw.

The Pentagon did not provide The Intercept with the scientific evidence behind the mandate. When asked whether the department assessed fertility consequences or established safeguards against unnecessary treatment, Pentagon officials pointed to Hegseth's health directives, statements from other Pentagon personnel, and the "High-T Department of War" video.

The VA already knows how this plays out. In 2018, the VA Office of Inspector General found that providers routinely started patients on testosterone without adequately documenting symptoms or confirming low levels. Approximately two out of three patients did not receive a documented discussion of risks and benefits before beginning treatment. The review found that VA providers frequently failed to conduct recommended follow-up monitoring after treatment started.

The inspector general made seven recommendations to correct the program. The VA implemented all seven, including a requirement that providers establish signs and symptoms of testosterone deficiency before testing. This is a higher standard than Hegseth's mandate, which calls for annual screening based on age alone, regardless of symptoms.

The Intercept asked the VA whether it has the clinical capacity to continue testosterone treatment for veterans who begin therapy under the Pentagon's new initiative, whether prescriptions would automatically continue after separation, and whether the two healthcare systems have coordinated on patient transitions.

The VA did not answer any of those questions.

Defense Department personnel data from 2024 show roughly 451,000 active-duty troops were age 31 or older, a conservative figure that excludes 30-year-olds. More than 1 million of the military's 1.27 million active-duty service members were men. Hundreds of thousands of asymptomatic, healthy soldiers are now slated for a screening protocol that medical experts advise against, followed by a treatment that carries real risks including acne, balding, breast tissue growth, impaired heart function, erectile dysfunction, and increased risk of death.

The initiative also intersects with a gap in military reproductive healthcare that Congress has been trying to close. TRICARE, the military's health insurance, generally does not cover assisted reproductive technologies, including in vitro fertilization and cryopreservation, which can cost tens of thousands of dollars. Both the House and Senate versions of the fiscal year 2026 defense authorization bill included provisions expanding that coverage. Neither provision survived final legislation.

Dobs put it bluntly: "Here we have men who are in their prime of reproduction, and we're causing a drop in their sperm counts when there really may not be sufficient benefit."

Rep. Chrissy Houlahan, D-Pa., an Air Force veteran and member of the House Armed Services Committee, noted that the announcement entirely excluded women from its framing. "Testosterone is important for both men and women," she said. "But when Hegseth says 'biological foundation,' clearly he has only one sex in mind."

Houlahan pushed for research into how military service affects women entering perimenopause and menopause, including the effects of toxic exposure, combat, and post-traumatic stress disorder. "There is little to no research" on those risk factors, she said.

"This announcement about testosterone proves that Secretary Hegseth is only concerned about reproductive health when it serves his own political and misogynistic agenda," Houlahan said.

The scientific record on testosterone and physical performance is unambiguous. A 2019 study found that men who received injected testosterone while engaged in intense exercise and a restricted diet designed to mimic strenuous military operations saw no gains in strength or endurance. A 2022 follow-up confirmed the finding: no increase in physical performance. Testosterone is tied to muscle mass, but it is not linked with actual strength.

Hegseth's predecessor as a purveyor of military fitness dogma was Theodore Roosevelt, whose fixation on masculine vigor in the face of perceived civilizational decay drove expansionist foreign policy and domestic eugenics. Hegseth wrote a 2016 book based on Roosevelt's "Man in the Arena" speech, carried a framed copy into combat at Guantánamo Bay, and last year tried to cut Pentagon ties with the Boy Scouts for allegedly abandoning "masculine values."

In his 2024 book, "The War on Warriors," Hegseth described a plot to manufacture "soft men, and a weak military," warning of "Pentagon pussies" and forces growing "fatter," "slower," and "effeminate." The testosterone mandate reads like the policy manifestation of those anxieties: a secretary who cannot accept that America's wars are failing decides the problem is hormonal.

A group of senators called out Hegseth last week, noting his department provided no evidence that the policy improves readiness, nor explained the scientific basis, costs, or risks of implementing it across the force. They pointed to "recent repeated efforts to redefine military culture around an exaggerated conception of masculinity."

Hegseth responded by telling Michigan Sen. Gary Peters that he had "Trump derangement syndrome."

The question is not whether some soldiers could benefit from testosterone replacement therapy. The question is why a secretary of war is mandating mass hormone screening without evidence, while his own department's healthcare system was recently reprimanded for getting it wrong, and while the wars he oversees continue to go badly.

All the testosterone in the world will not fix a war secretary who mistakes blood work for strategy.